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Abstract: In the last 15 years, crustacean fisheries have experienced billions of dollars in economic
losses, primarily due to viral diseases caused by such pathogens as white spot syndrome virus
(WSSV) in the Pacific white shrimp Litopenaeus vannamei and Asian tiger shrimp Penaeus monodon. To
date, no effective measures are available to prevent or control disease outbreaks in these animals,
despite their economic importance. Recently, double-stranded RNA-based vaccines have been shown
to provide specific and robust protection against WSSV infection in cultured shrimp. However, the
limited stability of double-stranded RNA is the most significant hurdle for the field application of
these vaccines with respect to delivery within an aquatic system. Polyanhydride nanoparticles have
been successfully used for the encapsulation and release of vaccine antigens. We have developed
a double-stranded RNA-based nanovaccine for use in shrimp disease control with emphasis on
the Pacific white shrimp L. vannamei. Nanoparticles based on copolymers of sebacic acid, 1,6-bis(pcarboxyphenoxy)hexane, and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane exhibited excellent safety
profiles, as measured by shrimp survival and histological evaluation. Furthermore, the nanoparticles
localized to tissue target replication sites for WSSV and persisted through 28 days postadministration.
Finally, the nanovaccine provided ~80% protection in a lethal WSSV challenge model. This study
demonstrates the exciting potential of a safe, effective, and field-applicable RNA nanovaccine that
can be rationally designed against infectious diseases affecting aquaculture.
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1. Introduction
Shrimp aquaculture is an $18.3 billion industry providing employment to approximately 1 million people annually and has important implications for global food security [1,2]. The Pacific white shrimp, Litopenaeus vannamei, is the most frequently cultured
species for human consumption [3]. Up to 40% of marine shrimp in production are lost
annually due to infectious diseases of viral etiology, such as infectious myonecrosis virus
(IMNV) and white spot syndrome virus (WSSV) [1]. In particular, WSSV is the most economically and globally significant shrimp pathogen decimating a tenth of shrimp production
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(~$1 billion) every year. Shrimp infected with WSSV develop white spots and succumb
to the pathogen within 2–7 days, with mortality as high as 100% [4]. The lack of effective
countermeasures against WSSV and other shrimp pathogens calls for urgent attention to
developing disease intervention approaches that are safe and efficacious [5]. In this respect,
vaccination strategies such as inactivated virus, subunit antigen, and DNA-based vaccines
against WSSV have shown promise at the laboratory scale [6,7]. However, the drawbacks,
such as variable efficacy, high manufacturing cost, and limited field applicability warrant
further research [6].
RNA interference (RNAi) in invertebrates is an antiviral cellular mechanism by which
a trigger, such as double-stranded RNA (dsRNA) or small interfering RNA (siRNA) starts
sequence-specific degradation of target mRNA, thereby preventing viral gene expression.
These dsRNA have been tested in a broad variety of settings, such as in plant pest control,
next-generation mosquitocides, and vaccine design. In aquaculture systems, the concept
of RNAi-based vaccines has been championed for several reasons: (a) RNAi works as
an antiviral immune response in shrimp; (b) it is pathogen-specific; and (c) it generates
a long-term protective immune response [5]. Previous work has shown that dsRNAbased vaccines are nontoxic, efficacious, and provide protection against a lethal dose of
WSSV [8,9]. However, in all the applications mentioned above, the main challenge for the
progression of a dsRNA-based vaccine from discovery to product and field application
is its environmental stability and manufacturing costs. We posit that the limitations to
dsRNA delivery in the field could be overcome using a nanocarrier delivery platform
that further enhances cellular uptake, establishes long tissue residence times, is dose
sparing, thereby reducing the cost and is adaptable for mass vaccinations. In this respect,
biodegradable polyanhydride nanoparticles have proven to be efficacious delivery systems
for antigen-based vaccines and drugs [10–14]. These carriers have been synthesized using
copolymers, based on sebacic anhydride (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH)
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), degrade via surface erosion [15].
The surface erosion ultimately excludes water from the bulk of the material and has been
shown to provide enhanced stability of encapsulated payloads [16], which could be critical
in an aquaculture setting. Furthermore, the ability to tailor copolymer compositions, and
therefore the polymer hydrophobicity, has also been shown to enable sustained antigen
release [16] as well as enhance antigen internalization by antigen-presenting cells [17,18].
In this proof-of-concept study, the first one to our knowledge, we combined two platform technologies—RNAi-based virus-specific dsRNA and a polyanhydride nanoparticlebased delivery platform—to develop a nanovaccine for aquaculture applications. The effect
of nanoparticle chemistry on safety, biodistribution, and persistence was evaluated in vivo
in L. vannamei. To mimic an oral route of administration, nanovaccines were injected via
reverse gavage to target the gastrointestinal epithelia. Finally, nanovaccine efficacy was
tested in a lethal WSSV challenge model in vivo in shrimp.
2. Materials and Methods
2.1. dsRNA Synthesis
For WSSV dsRNA generation, a plasmid with the potential to make a hairpin RNA
was constructed for a WSSV gene with proven protective capacity [19]. This construct was
transformed into an RNase III-deficient E. coli strain HT115 (DE3). Next, IPTG (isopropyl
β-D-1-thiogalactopyranoside)-induced HT115 cells were pelleted and the WSSV 477 dsRNA
was isolated using TRIzol reagent as per the manufacturer’s instructions (Thermo Fisher
Scientific, Grand Island, NY, USA). The quantity and purity of the dsRNA was ascertained
using NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, NC, USA). Finally, the
integrity of the dsRNA was checked using 1% standard agarose gel.
2.2. Polyanhydride and Nanoparticle Synthesis
Copolymers of 20:80 CPH:SA and 20:80 CPTEG:CPH were synthesized via melt
polycondensation as previously described [20,21] and characterized using 1 H nuclear
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magnetic resonance spectroscopy (VXR 300 MHz, Varian, Palo Alto, CA, USA) to assess
composition, purity, and molecular weight. The number average molecular weights were
approximately 20,154 Da and 8694 Da for 20:80 CPH:SA and 20:80 CPTEG:CPH, respectively,
and consistent with previous work [20,21].
Polyanhydride nanoparticles were synthesized using a nanoprecipitation technique
as previously described [22]. Briefly, 1 wt.% rhodamine B (Sigma Aldrich, St. Louis, MO,
USA) and polymer were dissolved in methylene chloride at a concentration of 20 mg/mL.
The solution was sonicated for 30 s before precipitating the nanoparticles into pentane
(at a 1:250 ratio of methylene chloride:pentane). The nanoparticles were then collected
and dried via vacuum filtration. During synthesis of 20:80 CPTEG:CPH nanoparticles, the
pentane was chilled in a liquid nitrogen bath due to the lower glass transition temperature
of CPTEG-containing polymers [21]. Nanoparticles encapsulating 11 wt.% dsRNA were
synthesized following the same process. Particle morphology and size were characterized
using scanning electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR, USA) and found
to be consistent with previous work [16,22].
2.3. Release Kinetics of dsRNA from Polyanhydride Nanoparticles
Nanoparticles loaded with 11 weight% dsRNA were incubated at a concentration of
10 mg nanoparticles per mL of saline (2% sodium chloride in RNase-free water) at 37 ◦ C.
Periodically, the nanoparticles were centrifuged to the bottom of the tube, and the saline
containing released dsRNA was removed and replaced with fresh saline. The released
dsRNA in the saline was quantified at each time point by reading the absorbance of the
sample at 260 nm with a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies)
for approximately 1 month. To determine the encapsulation efficiency, the release of dsRNA
was continued until the particles were completely degraded and no further dsRNA was
detected within the saline. The encapsulation efficiency was then calculated by dividing the
total amount of dsRNA released from the nanoparticles by the amount of dsRNA added
during nanoparticle synthesis.
2.4. Stability of dsRNA Released from Polyanhydride Nanoparticles
The dsRNA-containing nanoparticles were sonicated in 2% artificial sea salt solution
(1 mg particles/100 µL saline) and incubated for 1 hour at room temperature. After the
incubation, the particles were centrifuged briefly and the supernatant containing released
dsRNA was removed and analyzed on a standard 1% agarose gel.
2.5. Shrimp Rearing
Specific-pathogen free (SPF) L. vannamei were received from Shrimp Improvement
Systems (Islamorada, FL, USA). Animals were maintained as previously described [23].
After arrival, animals were acclimatized for 1–2 weeks in 1 ton fiberglass tanks filled with
artificial seawater made by mixing Crystal Sea Marinemix (Marine Enterprises International,
Baltimore, MD, USA) with municipal water to a salinity of 28–30 parts per thousand (ppt).
Water temperatures were maintained at 25–27 ◦ C. Tanks were constantly aerated with air
stone aeration and were outfitted with an oyster-shell airlift biofilter and activated carbon
filter. Water quality, including ammonia and nitrite levels, was measured weekly. The
animals were fed twice a day with Raceway plus commercial shrimp feed according to size
and developmental stage (Zeigler Bros, Gardners, PA, USA).
2.6. Nanovaccine Safety
SPF shrimp (~3 g) were injected via reverse gavage with 500 µg of either 20:80 CPH:SA
or 20:80 CPTEG:CPH nanoparticles suspended in 100 µL of water. Water-injected animals
were used as controls. Survival was monitored until 60 days postinjection. Shrimp body
weight was recorded at day 0 (initial weight) and at day 60 (final weight).
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2.7. Histopathology
At the termination of the bioassays, live shrimp were fixed by injecting Davidson’s
fixative (22% of 100% formalin, 33% of 95% ethanol, 11.5% glacial acetic acid and 33.5%
distilled water) at multiple places in the cephalothorax and abdominal regions. Shrimp
whole bodies were then immersed in fixative solution for 72 h at room temperature. Following fixation, shrimp were transferred to 75% ethanol. Shrimp were dissected into various
tissue sections and a blinded histopathological analysis was performed at the Aquaculture
Pathology Laboratory of the University of Arizona in Tucson, AZ, USA.
2.8. Biodistribution
SPF shrimp (~3 g) were injected via reverse gavage with 250 µg of 1% rhodamineloaded 20:80 CPH:SA or 20:80 CPTEG:CPH nanoparticles in 100 µL water. Animals injected
with water were used as controls. Animals were dissected into cephalothorax, hepatopancreas, gut, gills and stomach regions at 0, 2, 7, 14, 21 and 28 days postinjection. Fluorescent
images of the dissected tissues were collected with an in vivo Multispectral FX Pro imaging
system (Carestream, Rochester, NY, USA) using 510 nm excitation and 600 nm emission
filter wavelengths. A white light image was also captured to define the tissue boundaries
and regions of interest. Fluorescence measurements were performed at the same exposure
setting to compare all data sets to one another. Image Analysis NIH Image Jv1.47 m (U.S.
National Institutes of Health, Bethesda, MD, USA) was utilized to quantify the mean
fluorescent intensities (MFI) values. Briefly, a region of interest (ROI) was drawn around
each tissue sample utilizing the white light image. The same ROI was then applied to the
fluorescent image and the MFI quantified utilizing the Analyze→Measure function [24,25].
The fold change in fluorescence was calculated by dividing the MFI of an individual tissue
sample with the MFI of the corresponding tissue collected from controls. Experiments were
performed in duplicate with 3–4 animals per group per time point in each experiment.
2.9. Virus Stock Preparation
Virus inoculum was prepared from tissue of WSSV-infected animals as described
previously [23]. Tissue was collected from WSSV infected animals, macerated, and homogenized with sterile TN buffer (0.02 M Tris-HCl, 0.4 M NaCl, pH 7.4). The homogenate was
clarified three times by centrifuging at 14,000× g for 30 min; 15,000× g for 15 min; and
25,000× g for 60 min. The final supernatant after clarification was diluted 1:10 (~6.83 × 106
viral copy numbers/µL DNA) with 2% sodium chloride. The viral stock was then aliquoted
and stored at −80 ◦ C. For virus challenge experiments, the stock was diluted 1:7500 to get
the final concentration of ~9.1 × 102 viral copy numbers/µL DNA.
2.10. Bioassays for Survivability
SPF L. vannamei shrimp (~3 g) were divided into six experimental groups: (a) WSSV
477 dsRNA encapsulated in 20:80 CPTEG:CPH (Encap477 20:80 CPTEG:CPH) nanoparticles;
(b) WSSV 477 dsRNA encapsulated in 20:80 CPH:SA (Encap477 20:80 CPH:SA) nanoparticles;
(c) soluble WSSV 477 dsRNA (Soluble477 ); (d) soluble eGFP dsRNA (Soluble eGFP ) (nonshrimp sequence-specific vaccination control); (e) unvaccinated, unchallenged control
(negative); and (f) sham-vaccinated (sham). Each experimental group contained a total
of 30 shrimp (three replicates of 10 shrimp) except the negative control for which only
20 shrimp were used. Ten shrimp were stocked per fiberglass tank containing 50 gallons of
artificial seawater and an oyster-shell airlift biofilter with 28–30 ppt salinity. A temperature
of 28 ◦ C was maintained throughout the course of experiment.
Following acclimatization for at least 3 days, 100 µL of the nanovaccine (100 µg of 11%
dsRNA-loaded nanoparticles) was administered by reverse gavage to each shrimp to mimic
the oral route of administration. The animals in the soluble dsRNA group were given 11 µg
of dsRNA in water. The animals in the sham and negative control groups received water
by reverse gavage. At 72 h postvaccination, all shrimp (except the negative control group)
were challenged intramuscularly in the third abdominal segment with 100 µL of the WSSV
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virus stock (~ 9.1 × 102 viral copy numbers/µL DNA). Shrimp were fed and monitored for
mortality twice a day for 12–15 days postchallenge. Moribund shrimp were identified and
fixed for histopathology. Dead shrimp were removed in a timely manner and stored at −80 ◦ C
to be tested for the presence of virus load by qPCR. At termination, two animals per group
were fixed for histopathology and the remaining animals were stored at −80 ◦ C to be tested
for the presence of virus load by qPCR. These studies were performed in duplicate.
2.11. Quantitative Real Time PCR
DNA template from individual shrimp was extracted using the DNeasy blood and
tissue kit (Qiagen, Valencia, CA, USA). Muscle tissue was homogenized using glass grinders
followed by DNA extraction according to manufacturer’s instructions. The DNA was stored
at −80 ◦ C until use. Quantitative real-time PCR primers and standard were designed as
described previously [26]. The primers used were WSSV forward primer: 50 -TGG TCC
CGT CCT CAT CTC AG-30 ; WSSV reverse primer: 50 -GCT GCC TTG CCG GAA ATT A-30 ;
and the probe: 50 -FAM-AGC CAT GAA GAA TGC CGT CTA TCA CAC A-TAMRA-3’.
The qPCR reactions were performed using the Quantitect Probe kit (Qiagen) in 25 µL
reactions containing 3 µL of DNA template, 12.5 µL of Master Mix, 0.5 µL of TaqMan
probe, 1 µL of 20 µM WSSV forward primer, 1 µL of 20 µM WSSV reverse primer, and
7 µL of nuclease-free water. Each DNA sample was assayed in duplicate. Four different
dilutions of standard were used to generate the standard curve. The reactions were run
on a BioRad CFX96 real-time PCR machine (BioRad, Hercules, CA, USA) with cycling
conditions including 15 min of preincubation at 95 ◦ C followed by 35 cycles of 15 s at 95 ◦ C
and 1 min at 60 ◦ C [16]. Virus copy number was calculated using CFX Manager software
(BioRad) according to a standard curve.
2.12. Statistical Analysis
Statistical analysis was performed using JMP and SAS 9.4 software (SAS Institute,
Cary, NC, USA). For comparisons of multiple treatment groups, data were analyzed using
Tukey’s honestly significant difference (HSD). Differences were considered significant when
p < 0.05. For viral challenge data, a binomial generalized linear model was fitted, with
survival counts in the final day (12 DPI) as response variable and treatment levels and
experiment as fixed effects. In order to improve parameter estimation, Bayesian models
with normal vague priors for the regression coefficients were used. The models were
fitted with proc Genmod. All models were run using 3 chains with 2000 iterations for
burn-in and 10,000 for sampling after burn-in period, and convergence was studied with
the Gelman–Rubin statistic.
2.13. Principal Component Analysis (PCA)
The ordering of axes, as defined by the eigenvalues corresponding with the loadings
was used for defining parameters of multidimensional data, with the caveat that the first
PC, PC1, captured a majority of the variance in the data [27,28]. The integration through
PCA of discrete data with PCA parameterized continuous data was performed as described
previously [29–31]. In all cases, the data were mean-centered prior to analysis, and when
the units of the dimensions were different, then the data were normalized. The similarity of
systems was defined through comparison of Euclidean distances, where a shorter Euclidean
distance represents higher correlation or similarity.
3. Results
3.1. Polyanhydride Nanoparticles Provide Sustained Released of dsRNA
Polyanhydride nanoparticles encapsulating 11% WSSV 477 dsRNA were successfully
synthesized via nanoprecipitation. The average diameter of the resulting nanoparticles
was determined using ImageJ (version 1.46 r, NIH, Bethesda, MD, USA) and found to be
approximately 273 ± 126 nm (20:80 CPH:SA) and 219 ± 74 nm (20:80 CPTEG:CPH) for
nanoparticles loaded with rhodamine (Table 1). Nanoparticles loaded with 11% dsRNA had
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a mean diameter of 290 ± 160 nm and 164 ± 66 nm for 20:80 CPH:SA and 20:80 CPTEG:CPH,
respectively (Table 1) consistent with previous work [16,22]. The particles were then incubated
in saline for approximately 1 month to observe the release kinetics of dsRNA. The release
of dsRNA from both the 20:80 CPH:SA and 20:80 CPTEG:CPH nanoformulations displayed
near-zero order release kinetics after an initial burst (i.e., within the first hour of release). It is
known that the more hydrophobic CPH-rich copolymers have slower erosion rates [32,33].
Thus, the rate of dsRNA release from the 20:80 CPTEG:CPH nanoparticles was much slower
than that from the 20:80 CPH:SA nanoparticles (Figure 1). In addition, it was observed
that the initial burst and the dsRNA encapsulation efficiency were highly dependent on
nanoparticle chemistry. Approximately 90% of the dsRNA encapsulated within the 20:80
CPH:SA nanoparticles was released within the first hour and the encapsulation efficiency
of the dsRNA in these particles was 34%. By contrast, the dsRNA released from 20:80
CPTEG:CPH nanoparticles with a reduced initial burst (40%) and the encapsulation efficiency
of the dsRNA in these particles was 74% (Figure 1 and Table 1).

Figure 1. In vitro release kinetics of dsRNA-loaded nanoaparticles. Nanoparticles loaded with 11%
WSSV 477 dsRNA were incubated in saline for approximately 1 month and the release kinetics were
measured. Data are presented as the mean ± standard error of the mean (SEM) and are representative
of 3 replicates per formulation.

Figure 1. In vitro release kinetics of dsRNA-loaded nanoaparticles. N
WSSV 477 dsRNA were incubated in saline for approximately 1 m
were measured. Data are presented as the mean ± standard error o
resentative of 3 replicates per formulation.

3.2. dsRNA Released from Polyanhydride Nanovaccines is Stable

To determine whether the encapsulation process had an
stability of the dsRNA, an early time point postencapsulatio

3. Results
3.1. Polyanhydride
Nanoparticles Provide Sustained Released of dsRNA
Results nanoparticles
Polyanhydride
encapsulating
11%
477 dsRNA
were successfully
synthesized
via 3.
nanoprecipitation.
The average
diameter
of WSSV
the resulting
nanoparticles
was determined
using
3.1.
Polyanhydride
Nanoparticles
Provide Sustained
Sustained
Released
of dsRNA
dsRNA
Polyanhydride
nanoparticles
encapsulating
11%
WSSV
477
dsRNA
were
successfully
synthesized
3.1.
Polyanhydride
Nanoparticles
Provide
Released
of
via
nanoprecipitation.
The
average
diameter
of
the
resulting
nanoparticles
was
determined
using
ImageJ
(version
1.46
r,
NIH,
Bethesda,
MD,
USA)
and
found
to
be
approximately
273
±
126
nm
Polyanhydride
nanoparticles
encapsulating
11%
477 dsRNA
were successfully
synthesized
via
nanoprecipitation.
The
average
diameter
of WSSV
the
waswith
determined
using
ImageJ
(version
r,219
NIH,
Bethesda,
MD,
USA)
andresulting
found
tonanoparticles
be approximately
273 rhodamine
± 126 nm
(20:80
CPH:SA)1.46
and
±average
74
nm
(20:80
CPTEG:CPH)
for
nanoparticles
loaded
Polyanhydride
nanoparticles
encapsulating
11%
WSSV
477
dsRNA
were
successfully
synthesized
via
nanoprecipitation.
The
diameter
of
the
resulting
nanoparticles
was
determined
using
Polyanhydride
nanoparticles
encapsulating
11%
WSSV
477
dsRNA
were
successfully
synthesized
ImageJ
(version
1.46
r,
NIH,
Bethesda,
MD,
USA)
and
found
to
be
approximately
273
±
126
nm
Polyanhydride
nanoparticles
encapsulating
11%
WSSV
477
dsRNA
were
successfully
synthesized
(20:80
CPH:SA)
and
219
±
74
nm
(20:80
CPTEG:CPH)
for
nanoparticles
loaded
with
rhodamine
(Table
1).
Nanoparticles
loaded
withdiameter
11%
dsRNA
had
a mean
of 290
± 160
andnm
164 ± 66
via
nanoprecipitation.
The
average
of
the
resulting
nanoparticles
was
determined
using
via(version
nanoprecipitation.
The
average
diameter
of the
theand
resulting
nanoparticles
was
determined
using
ImageJ
1.46
NIH,
Bethesda,
MD,
USA)
found
to diameter
be approximately
273nm
± 126
via
nanoprecipitation.
The
average
diameter
of
resulting
nanoparticles
using
(20:80
CPH:SA)
andr,219
± 74
nm
(20:80
CPTEG:CPH)
nanoparticles
loaded
with
rhodamine
(Table
1).
Nanoparticles
loaded
with
11%
dsRNA
had
afor
mean
diameter
ofwas
290determined
±273
160
nm
and
164 work
± 66
nm
for
20:80
CPH:SA
and
20:80
CPTEG:CPH,
respectively
(Table
1)
consistent
with
previous
ImageJ
(version
1.46
r,
NIH,
Bethesda,
MD,
USA)
and
found
to
be
approximately
±
126
nm
ImageJ
(version
1.46
r,
NIH,
Bethesda,
MD,
USA)
and
found
to
be
approximately
273
±
126
nm
(20:80
CPH:SA)
and1.46
219r,±NIH,
74 nm
(20:80
CPTEG:CPH)
for
nanoparticles
loaded
with
rhodamine
ImageJ
(version
Bethesda,
MD,dsRNA
USA)
and
found
to be
approximately
273
± 126
nm
Vaccines 2022, 10, 1428
7 of
(Table
1).
Nanoparticles
loaded
with
11%
had
a
mean
diameter
of
290
±
160
nm
and
164
± 17
66
nm
for
20:80
CPH:SA
and
20:80
CPTEG:CPH,
respectively
(Table
1)
consistent
with
previous
work
(20:80
CPH:SA)
and
219
±
74
nm
(20:80
CPTEG:CPH)
for
nanoparticles
loaded
with
rhodamine
[16,22].
The
(20:80
CPH:SA) and
and 219
219
74 nm
nm
(20:80
CPTEG:CPH)
for
nanoparticles
loaded
with
rhodamine
(20:80
CPH:SA)
±±20:80
74
(20:80
nanoparticles
loaded
with
rhodamine
(Table
1).20:80
Nanoparticles
loaded
with
11%CPTEG:CPH)
dsRNA
hadfor
a mean
diameter
of 290
± 160
nmprevious
and 164 work
± 66
nm
for
CPH:SA
and
CPTEG:CPH,
respectively
(Table
1)
consistent
with
[16,22].
The1).
(Table
Nanoparticles
loaded
with
11%
dsRNA
had
aa mean
diameter
of
290
±± 160
nm
and
164
±± 66
(Table
1).
Nanoparticles
loaded
with
11%
dsRNA
had
mean
diameter
of
290
160
nm
and
164
66
(Table
1).CPH:SA
Nanoparticles
loadedCPTEG:CPH,
with 11% dsRNA
had a mean(Table
diameter
of 290 ± 160with
nm and
164 ± 66work
nm
for
20:80
and 20:80
respectively
1) consistent
previous
[16,22].
The
Encapsulation
nm
for
20:80
CPH:SA
and
20:80
CPTEG:CPH,
respectively
(Table
1)
consistent
with
previous
work
nm for
for
20:80 CPH:SA
CPH:SA and
and 20:80
20:80 CPTEG:CPH,
CPTEG:CPH, respectively
respectively (Table
(Table 1)
1) consistent
consistent with
with previous
previous
work
nm
20:80
work
Scanning
Electron
MicrosDiameter
[16,22].
The
Encapsulation
[16,22].
The
[16,22].
The
Efficiency
Chemistry
Structure
[16,22].
The
Table
1. Polyanhydride
Nanoparticle
Characterization.
Scanning
Electron
MicrosDiameter
copy
(Mean ± SEM) Encapsulation
Efficiency
Chemistry
Structure
Scanning copy
Electron Micros- (Mean
Diameter
(Mean
± SEM)
Encapsulation
Encapsulation
± SEM)
Efficiency
Chemistry
Structure
Scanning
Electron
MicrosDiameter
Encapsulation
Scanning
Electron
MicrosDiameter
(Mean
±
SEM)
Encapsulation
Scanning
Electron
MicrosDiameter
copy
(Mean
±
SEM)
Efficiency
Chemistry
Structure
Efficiency
Chemistry
Structure
Diameter Efficiency
(Mean
± SEM)
Chemistry
Structure
copy Microscopy (Mean
(Mean
± SEM)
SEM)
Chemistry
Structure
Scanning Electron
Efficiency
copy
(Mean
±
SEM)
copy
±
(Mean ± SEM)
(Mean
± SEM)
(Mean
±±SEM)
(Mean
SEM)
Vaccines 2022,
7 of 18
20:8010, x FOR PEER REVIEW
(Mean
± SEM)

20:80
CPH:SA
20:80 20:80
CPH:SA
+ 1%
Rhodamine
20:80
20:80 20:80
CPH:SA
CPH:SA
+ 1%CPH:SA
Rhodamine
CPH:SA
CPH:SA
++1%
Rhodamine
+ 1% Rhodamine
1% Rhodamine
+ 1% Rhodamine
+ 1% Rhodamine

273 ± 126 nm
273 ± 126 nm
± 126
273273
± 126
nm nm
126nm
nm
273
±273
126
nm
273
±±
126

N/A
N/A
N/A N/A
N/A
N/AN/A

20:80
20:80
CPTEG:CPH
20:80
20:80 20:80
20:80
+CPTEG:CPH
1%
Rhodamine
20:80
CPTEG:CPH
CPTEG:CPH
CPTEG:CPH
CPTEG:CPH
+ 1%
Rhodamine
+ 1% Rhodamine
CPTEG:CPH
1% Rhodamine
+ 1% Rhodamine
++1%
Rhodamine
+ 1% Rhodamine

219 ± 74 nm
219 ± 74 nm
219 ±219
74 nm
74 nm
74
nm
219219
± 74±±nm
219 ± 74 nm

N/A
N/A
N/A
N/A
N/A N/A
N/A

20:80
20:80
20:80
20:80
20:80
CPH:SA
20:80
CPH:SA
CPH:SA
CPH:SA
++CPH:SA
11%
dsRNA
20:80
11%
dsRNA
+ 11%
11% dsRNA
dsRNA
CPH:SA
+ 11%
dsRNA
+
CPH:SA
+ 11% dsRNA
+ 11% dsRNA
20:80 20:80
20:80
20:80
20:80
CPTEG:CPH
+ +
CPTEG:CPH
+
CPTEG:CPH
CPTEG:CPH
+
20:80
11% dsRNA
CPTEG:CPH
+
11% dsRNA
11%
dsRNA
20:80
11% dsRNA
CPTEG:CPH
11%
dsRNA+ +
CPTEG:CPH
11% dsRNA
11% dsRNA

290 ± 160 nm

33.8 ± 1.2%

290 ± 160 nm
290 ± 160 nm

33.8 ± 1.2%
33.8 ± 1.2%

290
160
nm
33.833.8
1.2%
160nm
nm 33.8
1.2%
290
±±
160
±±1.2%
290
±±290
160
nm
±±33.8
1.2%

Figure 1. In vitro release kinetics of dsRNA-loaded nanoaparticles. Nanoparticles
loaded
with 11%
66 nm
74.0
±± 1.0%
164164
±164
66±
nm
74.0 ±74.0
1.0%
±nm
66
nm74.0
1.0%
66
± 1.0%
WSSV 477 dsRNA were incubated in saline for approximately164
1 ±month
and the
release
kinetics
164
± 66
nm
74.0
± 1.0%
were measured. Data are presented as the mean ± standard error 164
of the
mean
and± are
rep± 66
nm(SEM)74.0
1.0%
164 ± 66 nm
74.0 ± 1.0%
resentative of 3 replicates per formulation.

3.2. dsRNA
dsRNA Released from Polyanhydride Nanovaccines is
Is Stable
detrimental effect on the
To determine whether the encapsulation process had any detrimental
stability
of
the
dsRNA,
an
early
time
point
postencapsulation
was
utilized. The dsRNA
stability
released from the 20:80 CPH:SA or 20:80 CPTEG:CPH nanoparticles
nanoparticles was stable and no
indication of
of degradation
degradation was
was observed
observed in
in comparison
comparison to
to the
dsRNA
indication
the unencapsulated
unencapsulated dsRNA
control (Figure
(Figure 2).
2). These
These results
results indicate
indicate the
the ability
ability of
of the
the polyanhydride
polyanhydride nanoparticles
nanoparticles to
to
control
release stable
stable dsRNA
dsRNA payloads.
release
payloads.

Figure 2.
2. Stability
Stability of
of released
released dsRNA
dsRNA from
from nanoparticles.
nanoparticles. Released
Released dsRNA
dsRNA from
from nanoparticles
nanoparticles was
was
Figure
evaluated
for
using
gel
electrophoresis.
evaluated for using gel electrophoresis.

3.3. Polyanhydride Nanovaccines Do Not Induce Adverse Effects In Vivo
To test the biocompatibility of the nanoparticles, shrimp were subjected to a high
dose (500 µg; 5-fold higher compared to the dose used for dsRNA delivery) of blank (i.e.,
empty) 20:80 CPH:SA or 20:80 CPTEG:CPH nanoparticles and monitored for survival,
weight gain and histopathological changes. No significant differences in survival were
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3.3. Polyanhydride Nanovaccines Do Not Induce Adverse Effects In Vivo
To test the biocompatibility of the nanoparticles, shrimp were subjected to a high dose
8 of 18
µg; 5-fold higher compared to the dose used for dsRNA delivery) of blank (i.e., empty)
20:80 CPH:SA or 20:80 CPTEG:CPH nanoparticles and monitored for survival, weight gain
and histopathological changes. No significant differences in survival were observed 60 days
postinjection
between animals
injected
with waterthe
(95%
survival)
and animals injected
with
survival) nanoparticles
(Figure
3A), affirming
excellent
biocompatibility
of these
either
20:80
CPH:SA
(85%
survival)
or
20:80
CPTEG:CPH
(95%
survival)
nanoparticles
nanoparticles.
(Figure 3A), affirming the excellent biocompatibility of these nanoparticles.
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Because the goal of the vaccination regimen is to sustain shrimp aquaculture in
Because the goal of the vaccination regimen is to sustain shrimp aquaculture in a
a safe and efficient manner, changes in shrimp weight gain pre- and post-nanoparticle
safe and efficient manner, changes in shrimp weight gain pre- and post-nanoparticle
administration were investigated. Interestingly, the animals injected with 20:80 CPH:SA
administration were investigated. Interestingly, the animals injected with 20:80 CPH:SA
(10.17 g) or 20:80 CPTEG:CPH (10.52 g) nanoparticles had higher final weights than control
(10.17 g) or 20:80 CPTEG:CPH (10.52 g) nanoparticles had higher final weights than conanimals (9.10 g) (Table 2). Most importantly, no weight loss was observed in the animals
trol animals (9.10 g) (Table 2). Most importantly, no weight loss was observed in the
that received the nanoparticle formulations compared to control animals.
animals that received the nanoparticle formulations compared to control animals.
Table 2. Shrimp weight gain post-nanoparticle administration.

Group

Average Initial Weight Average Final Weight Weight Gain (WF − WI)
(WI) (gm)
(gm)
(WF) (gm)

% Weight Gain [(WF −
WI)/WI] × 100
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Table 2. Shrimp weight gain post-nanoparticle administration.
Group

Average Initial Weight
(WI ) (gm)

Average Final Weight
(WF ) (gm)

Weight Gain
(WF − WI ) (gm)

% Weight Gain
[(WF − WI )/WI ] × 100

Control
20:80 CPTEG:CPH
20:80 CPH:SA

5.01 ± 0.18
4.80 ± 0.16
4.99 ± 0.17

9.10± 0.34 (a)
10.52 ± 0.21 (b)
10.17 ± 0.35 (b)

4.08
5.73
5.18

81.4
119.4
103.76

Data are represented as mean ± SEM. Treatments with different letters are significantly different from one another
at p < 0.05.

Finally, to ascertain that the nanoparticles did not induce any adverse effects in shrimp,
multiple tissue types, including stomach, hepatopancreas, gut, and gills, were evaluated
for histopathology in a blinded fashion. No gross histopathological lesions were observed
in shrimp tissue injected with any of the nanoparticles compared to control animal tissues
(Figure 3B). An in-depth analysis was performed to observe lymphoid organ spheroids, hemocytic nodules, hemocytic congestion (inflammation), and skeletal muscle necrosis because
these are hallmark histopathological indicators of pathology caused by infection and stress
in shrimp. The results demonstrated that animals injected with the 20:80 CPH:SA and 20:80
CPTEG:CPH nanoparticles exhibited excellent in vivo safety profiles and none of the markers
were found to be significantly different compared to the control animals (Table 3).
Table 3. Summary of histological findings in shrimp administered with 500 µg of blank nanoparticles.
Parameter

Control

20:80 CPTEG:CPH

20:80 CPH:SA

Hepatopancreas vacuolization
Enteric bacteria
Septic hepatopancreatic necrosis
Hemocytic nodules
Hemocytic congestion
Skeletal muscle necrosis
Lymphoid organ spheroids

0.62 ± 0.18
1.25 ± 0.47
0
0.25 ± 0.16
0.12 ± 0.12
0.75 ± 0.31
2.00 ± 0.0

0.85 ± 0.14
1.33 ± 0.66
0
0.42 ± 0.20
0.28 ±0.18
0.14 ± 0.14
1.75 ± 0.25

1.00 ± 0
1.50 ± 0.28
0.50 ± 0.50
0.37 ± 0.26
0.37 ± 0.18
0.87 ± 0.29
0.75 ± 0.25

Data are represented as mean ± SEM.

3.4. Polyanhydride Nanoparticles Exhibit Chemistry-Dependent Spatiotemporal Distribution In Vivo
Similar to pathogens that can have tissue or organ tropism, the nanoparticles also showed
differential spatiotemporal distribution in animals [24]. In order to study the effect of nanoparticle chemistry on their biodistribution in shrimp, animals were injected with 250 µg of 1%
rhodamine-loaded 20:80 CPH:SA or 20:80 CPTEG:CPH nanoparticles via reverse gavage. At
2 h following injection, fluorescence from both nanoparticle formulations was observed in
the cephalothorax, hepatopancreas, stomach, gut, and gills of the animals (Figure 4A). The
highest initial fluorescence in the nanoparticle-injected animals was observed in the gut tissue
(~15-fold over controls) followed by the gills (~10 fold over controls).
Although there was reduction in nanoparticle fluorescence in the cephalothorax,
stomach, and gut during the first 2 days postinjection, the fluorescence values stabilized
between days 2 and 21 (Figure 4B). A nanoparticle chemistry-dependent effect was observed
in the gills where animals injected with both nanoparticle formulations having similar
fluorescence values at day 0; however, animals receiving the 20:80 CPH:SA nanoparticles
demonstrated a reduction in fluorescence to baseline values within a week. In contrast,
shrimp injected with the 20:80 CPTEG:CPH nanoparticles continued to exhibit fluorescence
even at the termination of the study at day 28 (Figure 4B).
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3.5. Double-Stranded
Provide
Protection against
WSSV
between
days 2 and 21RNA-Based
(Figure 4B).Nanovaccines
A nanoparticle
chemistry-dependent
effect
was observed
in
the
gills
where
animals
injected
with
both
nanoparticle
formulations
having
To examine the efficacy of dsRNA-based nanovaccines against WSSV
infection in
similar
fluorescence
values
at
day
0;
however,
animals
receiving
the
20:80
CPH:SA
na-were preL. vannamei, 20:80 CPH:SA and 20:80 CPTEG:CPH nanovaccine formulations

pared and their performance compared to that of soluble dsRNA, which previously showed
high-level protection (96% survivability) against WSSV at 10 days postinjection (DPI) [16].
In the current studies, shrimp that received soluble dsRNA demonstrated 93% survivability,
while animals that received the dsRNA-based 20:80 CPH:SA nanovaccine were similarly
protected against WSSV with 80% mean survival and animals that received the dsRNA-
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based 20:80 CPTEG:CPH nanovaccine showed 55% mean survival 12 days postinfection, as
shown in Figure 5A. In contrast, there were no survivors in sham control groups at 12 days
postinfection. In addition, the administration of the soluble eGFP formulation provided 40%
protection against WSSV consistent with previous reports in which heterologous dsRNA
provides protective effects against WSSV [34,35]. The mean survival of all vaccinated
groups (Encap477 20:80 CPTEG:CPH, Encap477 20:80 CPH:SA and soluble477 ) were significantly different from the sham control group as per Bayesian analysis. At 5% level the
credible intervals compared to the sham control are 5.01:642.83 for CPH: SA, 12
5.43:643.55
for
Vaccines 2022, 10, x FOR PEER REVIEW
of 18
CPTEG:CPH and 6.88:644.40 for Soluble477 (Table 4). All negative control animals survived
during the full course of these experiments.
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3.6. Informatics Analysis
Principal component analysis was employed to analyze the concurrent effects of
nanovaccines on key vaccine efficacy parameters: survival, viral load and histopathology. A plot incorporating data from the WSSV challenge (survival), qPCR analysis (viral
load) and histopathology on three axes was generated with equal importance given to
each axis. Through PCA, the proximity of data points indicated the degree of correlation
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Table 4. The pairwise treatment differences from Bayesian analysis.
Treatment 1

Treatment 2

Estimate

Standard
Deviation

Lower HPD

Upper HPD

Encap477 20:80 CPTEG:CPH
Encap477 20:80 CPH: SA
Soluble477
Negative

Sham
Sham
Sham
Sham

251.84
252.48
253.66
930.27

192.17
192.18
192.16
586.33

5.0118
5.4316
6.8842
97.4592

642.83
643.55
644.4
2135.09

In addition, histopathology analysis of stomach, hepatopancreas, gut, and gill tissue revealed severe lesions characteristic of WSSV infection as well as advanced tissue destruction.
In contrast, tissues from nanoparticle-vaccinated groups had normal tissue architecture
similar to negative controls (Figure 5B and Table 5). Quantitative real-time PCR results
showed that the RNA-based nanovaccines reduced the viral load in the challenged animals.
Analysis of shrimp mortality showed that the virus actively multiplied inside the animals,
which is evident from the increase in viral copy numbers up to 1.6 × 108 WSSV copy
numbers/µL from the starting inoculum of ~9.1 × 104 WSSV copy numbers per shrimp.
The comparison between shrimp mortality and survival within the vaccinated groups
showed that both animals receiving both nanoparticle formulations had significantly (with
p values lower than 0.02) reduced virus multiplication (Figure 5C).
Table 5. Severity grade of necrosis and lesions caused by WSSV postchallenge.
Group

Hepatopancreas
Vacuolization

Lymphoid Organ
Spheroids

Hemocytic
Nodules

Skeletal Muscle
Necrosis

WSSV
Lesions

Negative
Sham
Encap477 20:80 CPTEG:CPH
Encap477 20:80 CPH:SA
Soluble477
SolubleeGFP

1
1.6 ± 0.33
1.6 ± 0.33
0
1
1.6 ± 0.33

0.5 ± 0.5
0
1 ± 0.57
0
0.66 ± 0.66
2 ± 0.57

0
0
0.33 ± 0.33
1±1
1±1
0

0
0.66 ± 0.66
0
0
0
0

0
2.66 ± 1.33
0
0
0
0

Data represented as mean ± SEM.

3.6. Informatics Analysis
Principal component analysis was employed to analyze the concurrent effects of
nanovaccines on key vaccine efficacy parameters: survival, viral load and histopathology.
A plot incorporating data from the WSSV challenge (survival), qPCR analysis (viral load)
and histopathology on three axes was generated with equal importance given to each
axis. Through PCA, the proximity of data points indicated the degree of correlation
among formulations. As expected, the negative control and sham vaccinated groups were
identified as having very different characteristics, demonstrated by the largest distance
between these two data points (Figure 6 and Figure S1). The negative control group was
highly correlated with Encap477 20:80 CPH:SA and Soluble477 on the histopathology and
survival axes. The ranking of the highest to lowest similarity compared to unchallenged
negative control group was: Encap477 20:80 CPH:SA; Soluble477 ; SolubleeGFP ; Encap477
20:80 CPTEG:CPH; and sham (Figure 6).
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with a dose of nanoparticles that was five-fold higher than that required for vaccine delivery.
gavage, even with a dose of nanoparticles that was five-fold higher than that required for
Blinded histopathological analysis confirmed that no histological abnormalities were caused
vaccine delivery. Blinded histopathological analysis confirmed that no histological abin the shrimp alimentary tract tissue or gills due to nanoparticles. Hemocytic congestion,
normalities were caused in the shrimp alimentary tract tissue or gills due to nanopartia marker of inflammation in shrimp, was also evaluated and found to be no different than
cles. Hemocytic congestion, a marker of inflammation in shrimp, was also evaluated and
that in control animals (Figure 3B and Table 3). Finally, shrimp weight gain, which is the most
found to be no different than that in control animals (Figure 3B and Table 3). Finally,
important contributor to the farm yield, showed that particles did not affect the normal shrimp
shrimp weight gain, which is the most important contributor to the farm yield, showed
development (Table 2). These results are in accordance with previous work demonstrating
that particles did not affect the normal shrimp development (Table 2). These results are in
safety of polyanhydride nanoparticles in a murine model [39].
accordance with previous work demonstrating safety of polyanhydride nanoparticles in
The effect of chemistry on nanoparticle uptake and distribution in mammalian systems
a murine model [39].
has been extensively evaluated [17,39]. Like a pathogen that can have tissue or organ tropism,
polyanhydride particles can also show differential spatiotemporal distribution [17,40]. We
tested if the nanoparticle chemistry impacts tissue biodistribution and persistence in L. vannamei. As expected, nanoparticles were present in the gut, no doubt facilitated by the route
of administration; however, within 2 h they were also visualized in the stomach, hepatopancreas, and cephalothorax. At day 0, depending on the tissue, both CPH:SA and CPTEG:CPH
particles exhibited fluorescence that was 2–15 fold higher compared to the controls and no
significant differences were observed between the two chemistries. Interestingly, at day 0, gill
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tissues showed very high fluorescence levels with both 20:80 CPH:SA and 20:80 CPTEG:CPH
nanoparticles. While our previous work has demonstrated that the particles migrate systemically [39] in other animal models, the mechanism(s) by which the nanoparticles trafficked to
the gills remains to be determined. It is important to note that gills are one of the target organs
for several viral pathogens such as Taura syndrome virus (TVS), yellowhead virus (YHV) and
WSSV [4,41]. Thus, the presence of nanoparticles in gills potentially contributes to protection
against diseases caused by these viruses.
Nanoparticle persistence is another important outcome to enable vaccinated animals
to be protected from the disease through different life stages (post-larva, juvenile, or adult).
Our previous work has shown that polymer properties such as glass transition temperature
(Tg ), and hydrophobicity can significantly affect the tissue residence time of nanoparticles
in mice [39]. Both CPH:SA and CPTEG:CPH nanoparticles persisted in alimentary tract
tissue and gills for at least 21 days postinjection. The combination of long persistence of
particles along with short life span of shrimp may compensate for the lack of adaptive
immunological memory and provide protection during the grow-out phase of farming.
The reduction in fluorescence observed between day 0 and day 2 may likely be due to
excretion of particles and the initial burst release of rhodamine from the particles. A distinct
nanoformulation chemistry effect was observed in the gills where 20:80 CPH:SA particle
fluorescence returned to baseline levels by day 7 postinjection, while the CPTEG:CPH
particles showed high intensity even 28 days later.
Vaccines based on dsRNA can be effectively used against several shrimp viruses [5],
however development of suitable delivery strategies for mass vaccination of shrimp in
aquatic systems is a major challenge. Oral administration to shrimp (i.e., through feed) is
by far the most appealing method of vaccine delivery. These experiments demonstrated
that our nanovaccine when administered directly to the gut provided significant protection
against a lethal dose of WSSV. A reverse gavage strategy for administration was used to
mimic oral delivery and the results indicated that the nanovaccines protected encapsulated
dsRNA from the gut environment and delivered stable and functional WSSV RNAi trigger.
The nanovaccines not only increased the survivability of challenged shrimp but also
reduced WSSV replication in vivo. This finding can have important implications in the
field as it is known that horizontal transmission of WSSV in a shrimp pond can either be by
direct contact of infected cadaver i.e., by cannibalism or by indirect water-borne route [42].
Regardless of the route of transmission, the reduced virus load may thus contribute to
abating the spread of WSSV in field conditions by lowering the available viral dose.
Although the 20:80 CPH:SA nanovaccine provided greater protection against infection
in this work than the 20:80 CPTEG:CPH nanovaccine, it is important to understand the
advantage of each nanoformulation. For example, the dsRNA release kinetics from the
20:80 CPH:SA nanoparticles resulted in a large initial burst, such that almost 90% of the
encapsulated dsRNA was released rapidly (Figure 1). Due to this large burst, high amounts
of dsRNA were likely available in the shrimp alimentary tract at the time of infection (72 h
post-vaccination) and enhanced protection. In contrast, the initial burst of dsRNA from the
20:80 CPTEG:CPH nanovaccine was lower in comparison to that from the 20:80 CPH:SA
nanovaccine. The CPH-rich chemistries are known to have slower erosion rates due to their
inherent hydrophobicity, and thus, reduced release rates of encapsulated payloads [32,33].
As demonstrated by the dsRNA release kinetics (Figure 1) and persistence of polyanhydride nanoparticles (Figure 4), we postulate that 20:80 CPTEG:CPH nanovaccine would
sustain the release of dsRNA (and thus availability of dsRNA within the shrimp) and
enhance protection against infection at later time points (i.e., several months) in comparison with 20:80 CPH:SA nanoparticles. In contrast, the early infection schedule (i.e., 72 h
post vaccination) is advantageous to the 20:80 CPH:SA nanovaccine. In order to design
a single nanoformulation that can provide protective immunity against both early and late
infections, it is conceivable that administering a cocktail of both the 20:80 CPH:SA and
20:80 CPTEG:CPH nanoformulations will enable both early and long-lasting immunity.
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Despite the reduced encapsulation efficiency, the 20:80 CPH:SA nanovaccine provided
protection against viral challenge similar to that provided by the soluble477 RNA (~80%)
demonstrating the dose sparing capabilities of the nanovaccine. This result is consistent
with previous studies in our laboratories with 20:80 CPH:SA microparticles, in which
we observed a 64-fold antigenic dose sparing capability in mice, compared to antigen
alone [11]. The encapsulation efficiency data (Table 1) indicate that shrimp administered
with 20:80 CPH:SA nanovaccine received approximately 4 µg of dsRNA, compared to
shrimp that received soluble477 dsRNA alone (11 µg). However, upon infection with
WSSV, both 20:80 CPH:SA and soluble477 dsRNA treated animals had similar rates of
survival (Figure 5). Therefore, 20:80 CPH:SA nanovaccine provided similar levels of disease
protection with third the amount of dsRNA. Furthermore, an important ramification of
these data is the use of the nanovaccine in the field settings where it can be mixed with
shrimp feed. Previous data from our lab have shown that polyanhydride nanovaccines
can protect the encapsulated cargo and be efficacious even when stored at relatively high
temperature of 40 ◦ C for at least 4 months [36]. Since shrimp farming is done in warmer
temperatures (~30 ◦ C), the temperature stability of the nanovaccine can be instrumental for
application in the temperate/tropical climate. In contrast, dsRNA exposed to ultraviolet
light loses its biological activity and structure in a matter of few hours [43].
Altogether, these data demonstrate the ability of the polyanhydride nanoparticle
delivery platform to deliver dsRNA antivirals to aquatic animals. WSSV, being the most
threatening of the shrimp viruses, was used in this study, however, the rapid tailoring of
dsRNA against other viruses can make this adaptable to other diseases too. Moreover,
the versatility offered by this technology to deliver a wide range of antibiotic, antiviral,
and antifungal molecules have the potential of improving global agriculture by disease
control in crustacean and finned fisheries settings. The end result is a novel product that
ultimately provides more effective, lower-dose therapies to benefit animal health, with
tremendous potential to thereby contribute to both enhanced food safety and security and
environmental health.
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